Paul Cook, MD
Infectious Disease · Greenville, NCNPI 1760482970
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,201 of the $13,492 with a category attached, or 83.0%. Gilead accounts for 85.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $11,246 and has fallen 92.6% since, to $834 in 2025. Among infectious disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $132.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$11K
- Viiv Healthcare Company$813
- Intervascular$655
- Merck$127
- Johnson & Johnson$106
- AbbVie$72
- plus $219 from 12 others
Across 259 payments — averaging $11,202 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.5M
- Janssen Research & Development, LLC$544K
- Gilead$372K
- AbbVie$200K
- Merck$117K
- Viiv Healthcare Company$70K
- plus $88K from 3 others
What the payments were for
- Consulting fees$6555%
- Travel & lodging$11,20183%
- Food & beverage$1,46611%
- Education$811%
- Gifts$881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 16 | $11,499 |
| Viiv Healthcare Company | 52 | $813 |
| Intervascular | 1 | $655 |
| Merck | 9 | $127 |
| Johnson & Johnson | 7 | $106 |
| AbbVie(2 entities) | 4 | $72 |
| Janssen Products, LP | 1 | $30 |
| Insmed, Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Theratechnologies Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Shionogi Inc | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $11 |
| Janssen Scientific Affairs, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InterGard$655
How this compares
$13,492 in reported general payments places this provider in the 90th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 210 | $818,482 |
| TivicayDolutegravir Sodium | 187 | $408,171 |
| PrezcobixDarunavir/Cobicistat | 156 | $375,305 |
| DovatoDolutegravir Sodium/Lamivudine | 93 | $248,107 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 47 | $234,937 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 46 | $150,316 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $96,473 |
| OzempicSemaglutide | 15 | $13,724 |
| JanuviaSitagliptin Phosphate | 13 | $12,025 |
| BelsomraSuvorexant | 12 | $4,766 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 18 | $3,871 |
| Lamivudine-ZidovudineLamivudine/Zidovudine | 20 | $2,122 |
| AbacavirAbacavir Sulfate | 12 | $1,604 |
| ValacyclovirValacyclovir Hcl | 18 | $947 |
| Ethambutol Hcl | 13 | $932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $11,499 | $818,482210 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Triumeq | $813 | $752,750305 claims |
| Johnson & JohnsonPrezcobix | $106 | $375,305156 claims |
| Janssen Products, LPSymtuza | $30 | $234,93747 claims |
| MerckJanuvia, Belsomra | $127 | $16,79225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 infectious disease providers in North Carolina.
Other infectious disease in Greenville
- Thomas GallaherGreenville$155K
- Rabindra GhimireGreenville$15K
- Alexandra StangGreenville$12K
- Michael RobinsonGreenville$4K
- David WohlChapel Hill$726K
- Cristina GasparettoDurham$613K
- Cornelius van DamGreensboro$556K
- William HarleyCharlotte$307K
- Joseph EronChapel Hill$195K
- William AlexanderCary$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.